References
- Antzelevitch C. (2010). M cells in the human heart. Circ Res 106:815–17.
- Carro J, Rodriguez JF, Laguna P, Pueyo E. (2011). A human ventricular cell model for investigation of cardiac arrhythmias under hyperkalaemic conditions. Philos Trans A Math Phys Eng Sci 369:4205–32.
- Cranefield PF, Wit AL, Hoffman BF. (1972). Conduction of the cardiac impulse. 3. Characteristics of very slow conduction. J Gen Physiol 59:227–46.
- Fermini B, Hancox JC, Abi-Gerges N, et al. (2015). A new perspective in the field of cardiac safety testing through the comprehensive in vitro proarrhythmia assay paradigm. J Biomol Screen 21:1–11.
- Gintant G, Sager PT, Stockbridge N. (2016). Evolution of strategies to improve preclinical cardiac safety testing. Nat Rev Drug Discov 15:451–71.
- Glinka A, Polak S. (2014). The effects of six antipsychotic agents on QTc–an attempt to mimic clinical trial through simulation including variability in the population. Comput Biol Med 47:20–6.
- Jerling M, Huan BL, Leung K, et al. (2005). Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects. J Clin Pharmacol 45:422–33.
- Kannankeril P, Roden DM, Darbar D. (2010). Drug-induced long QT syndrome. Pharmacol Rev 62:760–81.
- Kola I, Landis J. (2004). Can the pharmaceutical industry reduce attrition rates?. Nat Rev Drug Discov 3:711–15.
- Lawrence CL, Bridgland-Taylor MH, Pollard CE, et al. (2006). A rabbit Langendorff heart proarrhythmia model: predictive value for clinical identification of Torsades de Pointes. Brit J Pharmacol 149:845–60.
- Mctavish D, Goa KL, Ferrill M. (1990). Terfenadine. An updated review of its pharmacological properties and therapeutic efficacy. Drugs 39:552–74.
- Mirams GR, Cui Y, Sher A, et al. (2011). Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk. Cardiovasc Res 91:53–61.
- O’hara T, Virag L, Varro A, Rudy Y. (2011). Simulation of the undiseased human cardiac ventricular action potential: model formulation and experimental validation. PLoS Comput Biol 7:e1002061. doi: 10.1371/journal.pcbi.1002061.
- Okada J, Yoshinaga T, Kurokawa J, et al. (2015). Screening system for drug-induced arrhythmogenic risk combining a patch clamp and heart simulator. Sci Adv 1:e1400142.
- Paul SM, Mytelka DS, Dunwiddie CT, et al. (2010). How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 9:203–14.
- Polak S. (2013). In vitro to human in vivo translation - pharmacokinetics and pharmacodynamics of quinidine. ALTEX 30:309–18.
- Polak S, Wisniowska B, Fijorek K, et al. (2014). In vitro-in vivo extrapolation of drug-induced proarrhythmia predictions at the population level. Drug Discov Tod 19:275–81.
- Redfern WS, Carlsson L, Davis AS, et al. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58:32–45.
- ten Tusscher KH, Noble D, Noble PJ, Panfilov AV. (2004). A model for human ventricular tissue. Am J Physiol Heart Circ Physiol 286:H1573–89.
- ten Tusscher KH, Panfilov AV. (2006). Alternans and spiral breakup in a human ventricular tissue model. Am J Physiol Heart Circ Physiol 291:H1088–100.
- Weiss JN, Garfinkel A, Karagueuzian HS, et al. (2010). Early afterdepolarizations and cardiac arrhythmias. Heart Rhythm 7:1891–9.
- Wisniowska B, Mendyk A, Fijorek K, Polak S. (2014). Computer-based prediction of the drug proarrhythmic effect: problems, issues, known and suspected challenges. Europace 16:724–35.
- Wu J, Zipes DP. (2002). Early afterdepolarizations, U waves, and torsades de pointes. Circulation 105:675–6.
- Yap YG, Camm AJ. (2003). Drug induced QT prolongation and torsades de pointes. Heart 89:1363–72.